MedPath

Intermittent Fasting in Nonalcoholic Fatty Liver Disease

Not Applicable
Conditions
Insulin Resistance
Non-Alcoholic Fatty Liver Disease
Intermittent Fasting
Obesity
Gut Microbiota
Interventions
Behavioral: Calorie restriction
Registration Number
NCT04355910
Lead Sponsor
Shaoguan University
Brief Summary

Although preliminary evidence suggests that intermittent fasting mimic-diet (IFD) exerts stronger effects on body weight and metabolic parameters, which may link obesity, non-alcoholic fatty liver disease (NAFLD) and major chronic diseases, compared with continuous calorie restriction (CCR), there is a lack of well-powered intervention studies. This randomized controlled trial will test whether IFD, operationalized as the "5:2 diet," has stronger effects on anthropometric and body composition characteristics, and circulating metabolic biomarkers than CCR and a control regimen in adults with NAFLD.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
120
Inclusion Criteria
  • The diagnosed criteria of fatty liver by ultrasound were presence of two of the three following criteria: increased hepatic echogenicity compared with cortical of the right kidney, blurring of liver vasculature, and deep attenuation of the ultrasonographic signal.
Exclusion Criteria
  • Excessive alcohol consumption (ethanol > 140 g/wk for men and > 70 g/wk for women), cirrhosis, viral hepatitis, cardiovascular disease, cancer, any consumption of nonsteroidal anti-inflammatory drugs, corticosteroids or prescriptive medicine that affect liver function, lipid and glucose metabolism.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intermittent fasting mimic-diet (IFD)Calorie restrictionRestrict 75% energy on two non-consecutive days each week.
Continuous calorie restriction (CCR)Calorie restrictionA daily 25% energy-restricted Mediterranean-type diet
Primary Outcome Measures
NameTimeMethod
Body weightChange from baseline body weight at week 8

Change of body weight

Secondary Outcome Measures
NameTimeMethod
Gut microbiotaChange from baseline plasma bile acids and the gut microbiome at week 8

Changes of blood metabolites and the gut microbiome

Lipid profileChange from baseline plasma TG, TC and LDL at week 8

Plasma lipids levels

Insulin resistanceChange from baseline plasma glucose and insulin at week 8

Plasma glucose and insulin levels

Trial Locations

Locations (1)

Guangdong Medical University

🇨🇳

Dongguan, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath